AbbVie Inc. reported additional positive data from two phase 3 studies of risankizumab in chronic plaque psoriasis, an inflammatory skin disorder.

The North Chicago, Ill.-base company released additional ranked secondary goals, which showed significantly higher rates of skin clearance at week 16 and at one year of treatment, compared with ustekinumab.

The replicate studies, called ultIMMa-1 and ultIMMa-2, evaluated the drug against placebo and ustekinumab, which Johnson & Johnson unit Janssen Biotech Inc. markets as Stelara.

Skin clearance rates were measured via static Physician Global Assessment, or sPGA, a point scale used to evaluate psoriasis disease activity.

Abbvie said the most common adverse events for risankizumab in both studies was upper respiratory tract infection.

The company presented the new data at the 2018 American Academy of Dermatology annual meeting in San Diego.

Abbvie is developing risankizumab in collaboration with Boehringer Ingelheim GmbH.